Studies on the Expression Patterns of Class I PI3K Catalytic Subunits and Its Prognostic Significance in Colorectal Cancer

Cell Biochemistry and Biophysics

Volumn 62, Issue 1, 2012, Pages 47-54

  Cui, Binbin ^a   Tao, Ji ^a   Yang, Yanmei ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

AKT; Colorectal cancer; PI3K

Indexed keywords

ISOPROTEIN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE;

ARTICLE; CANCER STAGING; CHEMISTRY; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; ENZYME ACTIVE SITE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MALE; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS;

CATALYTIC DOMAIN; CLASS IA PHOSPHATIDYLINOSITOL 3-KINASE; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; PROGNOSIS; PROTEIN ISOFORMS; RNA, MESSENGER;

EID: 84855578581     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9257-6     Document Type: Article

References (42)

1. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M. J. (2009). Cancer statistics 2009. CA: A Cancer Journal for Clinicians, 59, 225-249.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., et al. (1990). Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. The New England Journal of Medicine, 322, 352-358.
3. Krook, J. E., Moertel, C. G., Gunderson, L. L., et al. (1991). Effective surgical adjuvant therapy for high-risk rectal carcinoma. The New England Journal of Medicine, 324, 709-715.
4. Hahn, W. C., & Weinberg, R. A. (2002). Rules for making human tumor cells. The New England Journal of Medicine, 347, 1593-1603.
5. Niedermeier, M., Hennessy, B. T., Knight, Z. A., et al. (2009). Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood, 113, 5549-5557.
6. Bader, A. G., Kang, S., Zhao, L., & Vogt, P. K. (2005). Oncogenic PI3K deregulates transcription and translation. Nature Review Cancer, 5, 921-929.
7. Carracedo, A., & Pandolfi, P. P. (2008). The PTEN-PI3K pathway of feedbacks and cross-talks. Oncogene, 27, 5527-5541.
8. Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009). Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Review Drug Discovery, 8, 627-644.
9. Garcia-Echeverria, C., & Sellers, W. R. (2008). Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene, 27, 5511-5526.
10. Chen, J. (2008). Is src the key to understanding metastasis and developing new treatments for colon cancer? Nature Clinical Practice Gastroenterology Hepatology, 5, 306-307.
11. Cantley, L. C. (2002). The phosphoinositide 3-kinase pathway. Science, 296, 1655-1657.
12. Wymann, M. P., Zvelebil, M., & Laffargue, M. (2003). Phosphoinositide 3-kinase signalling-which way to target? Trends in Pharmacological Sciences, 24, 366-376.
13. Edgar, K. A., Wallin, J. J., Berry, M., et al. (2010). Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Research, 70, 1164-1172.
14. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M., & Bilanges, B. (2010). The emerging mechanisms of isoform-specific PI3K signalling. Nature Review Molecular Cell Biology, 11, 329-341.
15. Graupera, M., Guillermet-Guibert, J., Foukas, L. C., et al. (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature, 453, 662-666.
16. Guillermet-Guibert, J., Bjorklof, K., Salpekar, A., et al. (2008). The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proceedings of the National Academy of Sciences of the United States of America, 105, 8292-8297.
17. Gilio, K., Munnix, I. C., Mangin, P., et al. (2009). Non-redundant roles of phosphoinositide 3-kinase isoforms alpha and beta in glycoprotein VI-induced platelet signaling and thrombus formation. The Journal of Biological Chemistry, 284, 33750-33762.
18. Ghigo, A., & Hirsch, E. (2008). Isoform selective phosphoinositide 3-kinase gamma and delta inhibitors and their therapeutic potential. Recent Patents on Inflammation & Allergy Drug Discovery, 2, 1-10.
19. Ogino, S., Nosho, K., Kirkner, G. J., et al. (2009). PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. Journal of Clinical Oncology, 27, 1477-1484.
20. Barault, L., Veyrie, N., Jooste, V., et al. (2008). Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. International Journal of Cancer, 122, 2255-2259.
21. Sujobert, P., Bardet, V., Cornillet-Lefebvre, P., et al. (2005). Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood, 106, 1063-1066.
22. Hickey, F. B., & Cotter, T. G. (2006). BCR-ABL regulates phosphatidylinositol 3-kinase-p110gamma transcription and activation and is required for proliferation and drug resistance. The Journal of Biological Chemistry, 281, 2441-2450.
23. Mizoguchi, M., Nutt, C. L., Mohapatra, G., & Louis, D. N. (2004). Genetic alterations of phosphoinositide 3-kinase subunit genes in human glioblastomas. Brain Pathology, 14, 372-377.
24. Kang, S., Denley, A., Vanhaesebroeck, B., & Vogt, P. K. (2006). Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proceedings of the National Academy of Sciences of the United States of America, 103, 1289-1294.
25. Bénistant, C., Chapuis, H., & Roche, S. (2000). A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene, 19, 5083-5090.
26. Yuan, T. L., & Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene, 27, 5497-5510.
27. Martin-Berenjeno, I., & Vanhaesebroeck, B. (2009). PI3K regulatory subunits lose control in cancer. Cancer Cell, 16, 449-450.
28. Wee, S., Wiederschain, D., Maira, S. M., et al. (2008). PTEN-deficient cancers depend on PIK3CB. Proceedings of the National Academy of Sciences of the United States of America, 105, 13057-13062.
29. Boller, D., Schramm, A., Doepfner, K. T., et al. (2008). Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. Clinical Cancer Research, 14, 1172-1181.
30. Ikenoue, T., Kanai, F., Hikiba, Y., et al. (2005). Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Research, 65, 4562-4567.
31. Sartore-Bianchi, A., Martini, M., Molinari, F., et al. (2009). PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research, 69, 1851-1857.
32. Ekstrand, A. I., Jönsson, M., Lindblom, A., Borg, A., & Nilbert, M. (2010). Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Familial Cancer, 9, 125-129.
33. Bader, A. G., Kang, S., & Vogt, P. K. (2006). Cancer-specific mutations in PIK3CA are oncogenic. Proceedings of the National Academy of Sciences of the United States of America, 103, 1475-1479.
34. Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., & Roberts, T. M. (2005). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America, 102, 18443-18448.
35. Colakoglu, T., Yildirim, S., Kayaselcuk, F., et al. (2008). Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms: Is PTEN loss predictor of local recurrence? American Journal of Surgery, 195, 719-725.
36. Bi, L., Okabe, I., Bernard, D. J., & Nussbaum, R. L. (2002). Early embryonic lethality in mice deficient in the p110beta catalytic subunit of PI 3-kinase. Mammalian Genome, 13, 169-172.
37. Bi, L., Okabe, I., Bernard, D. J., Wynshaw-Boris, A., & Nussbaum, R. L. (1999). Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110alpha subunit of phosphoinositide 3-kinase. The Journal of Biological Chemistry, 274, 10963-10968.
38. Ali, K., Bilancio, A., Thomas, M., et al. (2004). Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature, 431, 1007-1011.
39. Okkenhaug, K., Bilancio, A., Farjot, G., et al. (2002). Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science, 297, 1031-1034.
40. Sasaki, T., Irie-Sasaki, J., Horie, Y., et al. (2000). Colorectal carcinomas in mice lacking the catalytic subunit of PI(3)K-gamma. Nature, 406, 897-902.
41. Semba, S., Itoh, N., Ito, M., et al. (2002). Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clinical Cancer Research, 8, 3824-3831.
42. Barbier, M., Attoub, S., Calvez, R., et al. (2001). Tumour biology. Weakening link to colorectal cancer? Nature, 413, 796.